Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

Autores de IIS La Fe

• José Muñoz Langa

  Autor

Participantes ajenos a IIS La Fe

• Garcia-Escobar, I
• Beato-Zambrano, C
• Vazquez, EB
• Portero, BO
• Gutierrez-Abad, D
• Martin, AJM
• Canc Thrombosis Working Grp Spanis

Grupos

• Investigación Clínica y Traslacional en Cáncer

Abstract

The association between venous thromboembolism (VTE) and cancer has been recognized for more than 100 years. Numerous studies have been performed to investigate strategies to decrease VTE incidence and to establish whether treating VTE impacts cancer progression and overall survival. Accordingly, it is important to understand the role of the hemostatic system in tumorigenesis and progression, as there is abundant evidence associating it with cell survival and proliferation, tumor angiogenesis, invasion, and dissemination, and metastasis formation. In attempts to further the scientific evidence, several studies examine survival benefits in cancer patients treated with anticoagulant therapy, specifically treatment with vitamin K antagonists, unfractionated heparin, and low-molecular-weight heparin. Several studies and meta-analyses have been conducted with a special focus on brain tumors. However, no definitive conclusions have been obtained, and more well-designed clinical trials are needed.

Keywords

• Venous thromboembolism; Overall survival; Vitamin K antagonists; Unfractionated heparin; Low-molecularweight heparin; Brain tumor